Tesis
Evaluación de la hemovacuna y hemovacuna ozonificada como tratamiento de anemia en ovinos de la estación experimental Tunshi.
Fecha
2022-04-27Registro en:
Galeas Dután, Mónica Vanessa. (2022). Evaluación de la hemovacuna y hemovacuna ozonificada como tratamiento de anemia en ovinos de la estación experimental Tunshi. Escuela Superior Politécnica de Chimborazo. Riobamba.
Autor
Galeas Dután, Mónica Vanessa
Resumen
The present research evaluated Hemovaccine and ozonated Hemovaccine as anemia treatment in sheep at the Tunshi Experimental Station. The duration of the research was 70 days divided into 52 days for: selection of sheep, preparation of livestock, shearing, and collection of initial samples, 15 days for application of the treatments, 3 days for collection of final samples, blood components of the red, white and platelet series were evaluated by means of laboratory analysis. The experimental units were assigned under a Completely Randomized Design (CRD) applying an analysis of Variance (ADEVA), with a probability (P ≤0.05). A total of 15 sheep were used applying 3 treatments: hemovaccine, ozonated hemovaccine and a control with 5 replicates for each treatment. To evaluate the effectiveness of the treatments, the separation of means according to Duncan at 5% was used. In addition, descriptive statistics were applied to determine the degree of anemia of the cattle at the beginning and end of the study. For the economic analysis, the benefit/cost formula was used. The results of the evaluation indicated that the sheep went from a moderate to a mild degree of anemia. In addition, the blood components slightly improved the health status of the animals. The highest efficiency was registered in the ozonified hemovaccine treatment (T2), highlighting that the mean corpuscular volume (MCV), white blood cells and platelets (PLT) were among the reference values; the effectiveness of the treatments in relation to weight gain did not register significant differences (P>0.05). Hemovaccine and ozonated hemovaccine had a positive influence on the treatment of anemia, and the highest profitability was obtained with the ozonated hemovaccine treatment (T2) reaching a benefit/cost of $ 1.28. It is advisable to extend the application time of the experimental treatments.